• Tweet
• Sharebar

• Tweet

Leading Californian life sciences companies announced they’re creating stronger ties with China to develop drugs and delivery channels into a modernizing China.

Similarly, business trade groups like BIOCOM are sending contingents to China to create partnerships with the government and development officials for cross-promoting products and services abroad.

Joe Panetta, Chief Executive Officer of BIOCOM- a locally based group that represents about 500 life sciences industries said, “We’re developing a strategy to more proactively promote all the services we can provide out of San Diego.”

Panetta also said that next month the association plans to sign a memorandum of understanding with a Beijing development organization. The aim is to create a kind of ties that will drive business in both countries.

Panetta remarked, “We hear a lot about the concern of outsourcing to China — that they have cheap labor. While they might have low-cost labor in terms of people who can do basic research, run sequencing machines and analyze data, they have very little experience when it comes to developing those products and commercializing those products.”

By means of linking BIOCOM with Beijing, Panetta acknowledged, corporations concerned with increasing valuable commercialization skills will have an opportunity for doing business.

Whereas China has completed a huge increase in its manufacturing and drug testing processes, industry commentators state that it has much knowledge to gain from the United States in terms of constructing fresh life sciences businesses and bringing drugs to the Chinese market.

A privately held startup based in Camel valley – Huya Bioscience International, is leveraging its partnerships with Chinese educational institutions and research centers concerned with advancing their commercial skills. Huya’s group of China-based “drug hunters” also taking advantage from the tie – they obtain a direct look at compounds Huya might look to on-license.

An anti-arrhythmic drug entrant and a treatment for cancer are the two of the products that the company will promote.

President and CEO of Huya, Mireille Gingras said, “We’re capitalizing on the explosion and growth of the Chinese biopharma industry,” and “We reduce the risk, the cost and the time because we in-license compounds that are already validated in China.”

In order to speed up their study, cut costs linked with preclinical and clinical trials, or both, other San Diego-based drug developers are building closer partnerships with China.